Cotreatment of PBLs, activated T cells, or HUVECs with scFvCD7:sFasL and several classes of antileukemia agents. PBLs (A), activated T cells (B), and HUVECs (C) were treated with scFvCD7:sFasL (40 ng/mL) combined with vincristine (0.5 ng/mL), L-744832 (25 μM), or bortezomib (40 nM). Apoptosis was assessed by annexin V/PI staining.